A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate huntington disease

JAMA Neurology

Volumn 70, Issue 1, 2013, Pages 25-33

  Dorsey, E Ray ^a,b  

^a European Huntington's Disease Network   (United States)

^b not available   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIMEBON; PLACEBO; INDOLE DERIVATIVE;

ANXIETY; ARTICLE; BEHAVIOR; BRAIN FUNCTION; CHOREA; CLINICAL INTERVIEW; CLINICAL INTERVIEW BASED IMPRESSION OF CHANGE; COGNITION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; FALLING; FATIGUE; HUMAN; HUNTINGTON CHOREA; INSOMNIA; INTERVIEW; MAJOR CLINICAL STUDY; MINI MENTAL STATE EXAMINATION; MOTOR PERFORMANCE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SOMNOLENCE; THERAPY EFFECT; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; XEROSTOMIA; AUSTRALIA; COMORBIDITY; CONTROLLED CLINICAL TRIAL; FEMALE; MALE; MIDDLE AGED; NORTH AMERICA; PSYCHOLOGICAL RATING SCALE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

AUSTRALIA; COMORBIDITY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HUNTINGTON DISEASE; INDOLES; MALE; MIDDLE AGED; NORTH AMERICA; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84875552322     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Walker FO. Huntington's disease. Lancet. 2007;369(9557):218-228.
2. Beglinger LJ, Adams WH, Paulson H, et al. Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease. J Clin Psychopharmacol. 2009;29(5):484-487.
3. Bachurin SO, Shevtsova EP, Kireeva EG, Oxenkrug GF, Sablin SO. Mitochondria as a target for neurotoxins and neuroprotective agents. Ann N Y Acad Sci. 2003; 993:334-349.
4. Sabbagh MN, Shill HA. Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs. 2010;11(1):80-91.
5. Bezprozvanny I. The rise and fall of Dimebon. Drug News Perspect. 2010;23(8): 518-523.
6. Kim J, Moody JP, Edgerly CK, et al. Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease. Hum Mol Genet. 2010;19(20):3919-3935.
7. Mochel F, Haller RG. Energy deficit in Huntington disease: why it matters. J Clin Invest. 2011;121(2):493-499.
8. Kieburtz K, McDermott MP, Voss TS, et al; Huntington Disease Study Group DIMOND Investigators. A randomized, placebo-controlled trial of latrepirdine in Huntington disease [published correction appears in Arch Neurol. 2010;67(4):492]. Arch Neurol. 2010;67(2):154-160.
9. [published correction appears in Arch Neurol. 2010;67(4):492]
10. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord. 1996;11(2):136-142.
11. Shoulson IKR, Rubin A, Goldblatt D, et al. Assessment of functional capacity in neurodegenerative movement disorders: Huntington's disease as a prototype. In: Munsat TL, ed. Quantification of Neurological Deficit. Boston, MA: Butterworth; 1989:271-283.
12. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-198.
13. Tombaugh TN, McIntyre NJ. The Mini-Mental State Examination: a comprehensive review. J Am Geriatr Soc. 1992;40(9):922-935.
14. Joffres C, Graham J, Rockwood K. Qualitative analysis of the Clinician Interview-Based Impression of Change (Plus): methodological issues and implications for clinical research. Int Psychogeriatr. 2000;12(3):403-413.
15. Litvinenko IV, Odinak MM, Mogil'naya VI, Emelin AY. Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial). Neurosci Behav Physiol. 2008;38(9):937-945.
16. Minett TS, Thomas A, Wilkinson LM, et al. What happens when donepezil is suddenly withdrawn? an open label trial in dementia with Lewy bodies and Parkinson's disease with dementia. Int J Geriatr Psychiatry. 2003;18(11):988-993.
17. Orgogozo JM, Rigaud AS, Stöffler A, Möbius HJ, Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke. 2002;33(7):1834-1839.
18. Folstein SE. Huntington's Disease: A Disorder of Families. Baltimore, MD: Johns Hopkins University Press; 1989.
19. Doody RS, Gavrilova SI, Sano M, et al; Dimebon Investigators. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008;372(9634):207-215.
20. Hoth KF, Paulsen JS, Moser DJ, Tranel D, Clark LA, Bechara A. Patients with Huntington's disease have impaired awareness of cognitive, emotional, and functional abilities. J Clin Exp Neuropsychol. 2007;29(4):365-376.
21. Paulsen JS, Ready RE, Hamilton JM, Mega MS, Cummings JL. Neuropsychiatric aspects of Huntington's disease. J Neurol Neurosurg Psychiatry. 2001; 71(3):310-314.
22. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308-2314.
23. Galasko D, Bennett D, Sano M, et al; The Alzheimer's Disease Cooperative Study. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S33-S39.
24. Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry. 2007;164(7):1035-1043.
25. Molenberghs G, Thijs H, Jansen I, et al. Analyzing incomplete longitudinal clinical trial data. Biostatistics. 2004;5(3):445-464.
26. Little RJA, Rubin DB. Statistical Analysis With Missing Data. 2nd ed. Hoboken, NJ: Wiley & Sons; 2002.
27. Landis JR, Cooper MM, Kennedy T, Koch GG. A computer program for testing average partial association in three-way contingency tables (PARCAT). Comput Programs Biomed. 1979;9(3):223-246.
28. Bachurin S, Bukatina E, Lermontova N, et al. Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann N Y Acad Sci. 2001;939: 425-435.
29. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med. 2004;351(24):2509-2518.
30. Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry. 2005;76(7):934-939.
31. Videnovic A, Bernard B, Fan W, Jaglin J, Leurgans S, Shannon KM. The Montreal Cognitive Assessment as a screening tool for cognitive dysfunction in Huntington's disease. Mov Disord. 2010;25(3):401-404.
32. Tabrizi SJ, Scahill RI, Durr A, et al; TRACK-HD Investigators. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol. 2011;10(1):31-42.
33. Cubo E, Shannon KM, Tracy D, et al. Effect of donepezil on motor and cognitive function in Huntington disease. Neurology. 2006;67(7):1268-1271.
34. de Tommaso M, Specchio N, Sciruicchio V, Difruscolo O, Specchio LM. Effects of rivastigmine on motor and cognitive impairment in Huntington's disease. Mov Disord. 2004;19(12):1516-1518.
35. Ondo WG, Mejia NI, Hunter CB. A pilot study of the clinical efficacy and safety of memantine for Huntington's disease. Parkinsonism Relat Disord. 2007;13(7): 453-454.
36. Weir DW, Sturrock A, Leavitt BR. Development of biomarkers for Huntington's disease. Lancet Neurol. 2011;10(6):573-590.
37. Klein C, Krainc D, Schlossmacher MG, Lang AE. Translational research in neurology and neuroscience 2011: movement disorders. Arch Neurol. 2011;68 (6):709-716.
38. Risks GH. Mortality and Burden of Diseases Attributable to Selected Major Risks. Geneva, Switzerland: World Health Organization; 2009.